文献速递肝肾功能剂量调整药物相互作用

达沙布韦的临床药代动力学特征

Clinical Pharmacokinetics of Dasabuvir.
PubMed 文献 · Clin Pharmacokinet · 2017-01-01

达沙布韦是用于慢性丙型肝炎治疗的NS5B非核苷抑制剂,主要经CYP2C8代谢,具线性药代动力学,半衰期约5-8小时,需每日两次给药。轻至重度肾功能不全及透析不影响其暴露,轻中度肝损伤无显著改变,但重度肝损伤暴露显著增加。与强CYP2C8抑制剂合用暴露增加超十倍,与强CYP3A诱导剂合用降低55-70%,故禁止与强CYP2C8抑制剂或强CYP3A/CYP2C8诱导剂合用。

要点

  • 达沙布韦主要经CYP2C8代谢,强CYP2C8抑制剂合用暴露增加超十倍,禁忌合用。
  • 强CYP3A诱导剂合用降低达沙布韦暴露55-70%,禁忌合用。
  • 轻至重度肾功能不全及透析无需调整剂量。

核心结论

  • 达沙布韦药代动力学特征明确,主要经CYP2C8代谢,药物相互作用风险集中在CYP2C8和CYP3A途径。

研究设计与样本

  • 综述类文章,检索范围未在摘要中明确报告。

主要发现

  • 达沙布韦呈线性药代动力学,终末半衰期约5-8小时,支持每日两次给药。
  • 代谢物M1为主要血浆代谢物,保留抗病毒活性,半衰期与母药相似。
  • 亚洲受试者暴露与白人受试者相当。
  • 健康受试者与HCV感染患者药代动力学特征相似。
  • 轻、中、重度肾功能不全或透析不显著改变达沙布韦药代动力学参数。

关键数值与推荐

  • 轻或中度肝损伤者达沙布韦药代动力学参数无显著改变,重度肝损伤者暴露显著增加。
  • 与强CYP2C8抑制剂合用暴露增加大于十倍,与强CYP3A抑制剂合用暴露增加小于50%。
  • 与CYP3A诱导剂合用暴露降低55-70%。
  • 禁止与强CYP2C8抑制剂或强CYP3A/CYP2C8诱导剂合用。
  • 达沙布韦应与食物同服以最大化吸收。

临床怎么用

  • 临床使用达沙布韦前应评估合并用药,避免与强CYP2C8抑制剂或强CYP3A/CYP2C8诱导剂合用。
  • 重度肝损伤患者使用达沙布韦需警惕暴露增加,轻中度肝损伤及肾功能不全者通常无需调整剂量。
  • 达沙布韦应与食物同服,以最大化吸收。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dasabuvir is a nonstructural (NS) 5B non-nucleoside inhibitor of the hepatitis C virus (HCV) used in combination with ombitasvir/paritaprevir/ritonavir for the treatment of chronic HCV infection. It is primarily metabolized by cytochrome P450 (CYP) 2C8, with a minor contribution from CYP3A. Biotransformation of dasabuvir forms the M1 metabolite, which retains antiviral activity. Dasabuvir exhibits linear pharmacokinetics with a terminal half-life of approximately 5-8 h, allowing for twice-daily dosing. The M1 metabolite of dasabuvir is the major metabolite in plasma and has a half-life similar to that of dasabuvir. Dasabuvir exposures in Asian subjects are comparable with Caucasian subjects. The pharmacokinetic characteristics of dasabuvir are similar between healthy subjects and HCV-infected patients, and are not appreciably altered by mild, moderate, or severe renal impairment or dialysis. Dasabuvir pharmacokinetic parameters were not significantly altered in subjects with mild or moderate hepatic impairment; however, exposures were significantly increased in subjects with severe hepatic impairment. Dasabuvir should be administered with food to maximize absorption. Coadministration of dasabuvir with a strong CYP2C8 inhibitor increased dasabuvir exposures by greater than tenfold, whereas coadministration with strong CYP3A inhibitors increased dasabuvir exposures by less than 50%. Furthermore, coadministration of dasabuvir with a CYP3A inducer decreased dasabuvir exposures by 55-70%. Coadministration of dasabuvir with strong CYP2C8 inhibitors or strong CYP3A/CYP2C8 inducers is contraindicated. Results from several drug interaction studies demonstrated that dasabuvir in combination with ombitasvir/paritaprevir/ritonavir can be coadministered with most comedications that are commonly prescribed in HCV-infected patients.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. King JR, Zha J, Khatri A, et al. Clinical Pharmacokinetics of Dasabuvir. Clin Pharmacokinet. 2017. PMID: 28258380. doi:10.1007/s40262-017-0519-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。